search
Back to results

Effect of Transcutaneous Electrostimulation (TENS) on Pain and Physical Function in Patients With Knee Osteoarthritis (ETRELKA)

Primary Purpose

Osteoarthritis, Knee

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
TENS
Sham TENS
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men and women of at least 18 years of age
  • Clinical or radiological diagnosis of knee OA according to the criteria of the American College of Rheumatology
  • Knee pain lasting for six months or longer
  • Radiographic evidence of at least one osteophyte at the tibiofemoral joint (Kellgren-Lawrence grade ≥ 2) or one or more of the following signs and symptoms in the knee; restricted range of motion, pain in motion, crepitations, morning stiffness
  • Written informed consent

Exclusion Criteria

  • Patients diagnosed with rheumatoid arthritis or other musculoskeletal diseases affecting lower extremities
  • Relevant effusion in the index knee
  • Known current or remittent cancer
  • Carry cardiac pacemaker or defibrillator in situ
  • Knee surgery in previous 6 months
  • Received treatment with arthrocentesis
  • Intra-articular injection of steroids in previous 3 months
  • Inability to understand instructions or to give informed consent

Sites / Locations

  • Institute of Social and Preventive Medicine (ISPM), University of Bern

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

TENS

Sham TENS

Arm Description

Transcutaneous Electrical Nerve Stimulation

Sham Transcutaneous Electrical Nerve Stimulation

Outcomes

Primary Outcome Measures

WOMAC pain subscale

Secondary Outcome Measures

WOMAC global subscale
WOMAC physical function subscale
Overall pain measured on VAS
Hospital anxiety and depression scale
Aberdeen measure of participation
Mean analgesic intake per patient
Number of drop-outs because of adverse events
Number of patients experiencing local adverse events
Number of patients experiencing any side effects
Number of patients experiencing serious side effects
Number of drop-outs
WOMAC pain subscale

Full Information

First Posted
May 30, 2013
Last Updated
April 11, 2016
Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
Arco Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT01875042
Brief Title
Effect of Transcutaneous Electrostimulation (TENS) on Pain and Physical Function in Patients With Knee Osteoarthritis
Acronym
ETRELKA
Official Title
Does Transcutaneous Electrical Nerve Stimulation (TENS) Affect Pain and Function in Patients With Osteoarthritis of the Knee? ETRELKA, a Randomised Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
January 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
Arco Foundation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The proposed study is a multi-center, randomized, double blind (patient and assessor), sham controlled clinical trial using a parallel 2 group design recruiting 220 patients of at least 18 years of age. The investigators will include patients presenting with clinically and radiologically diagnosed knee OA according to the criteria of the American College of Rheumatology, who experienced knee pain lasting for at least six months, and were diagnosed with radiographic severity of ≥ 2 on the Kellgren-Lawrence grading system or had one or more of the following signs and symptoms in the knee; restricted range of motion, pain in motion, crepitations, morning stiffness. Patients will be randomly allocated to receive TENS or sham TENS for 3 weeks.
Detailed Description
Background Osteoarthritis (OA) is the most common arthritic condition, which is one of the leading causes of disability in adults. Currently, no treatment can stop or reverse the progressive joint degeneration caused by OA. Most clinical interventions aim to improve pain and physical function. Transcutaneous electrical nerve stimulation (TENS) is widely used in the management of knee OA to relieve osteoarthritic pain and facilitate the performance of therapeutic activities in order to maintain or improve physical function. Although its use is widespread, the available evidence is of questionable quality. An adequately sized and well conducted randomized controlled trial (RCT) investigating the effectiveness and safety of TENS as treatment modality for knee OA is warranted to assist clinicians and policy makers to make decisions that are based on high-quality evidence, ultimately optimizing delivery of health-care in knee OA. Objective To determine TENS safety and effectiveness on pain and physical function compared to sham TENS in patients with knee OA. Methods Multi-center, randomized, double blind (patient and assessor), sham controlled clinical trial using a parallel 2 group design. Patients will be randomly allocated to receive TENS or sham TENS for 3 weeks. Informed consent of eligible patients will be obtained prior to randomization. Patients will be assigned on a 1:1 basis to the TENS or sham TENS group. Randomization will be centralized using randomization software and an electronic randomization form, generated by the trial coordinating centre (CTU Bern). Patients will be randomized once demographic data and selection criteria are completed by the recruiting physician in an electronic form. Randomization will be stratified according to treatment centre, TENS naivety and clinical severity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
220 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TENS
Arm Type
Experimental
Arm Description
Transcutaneous Electrical Nerve Stimulation
Arm Title
Sham TENS
Arm Type
Sham Comparator
Arm Description
Sham Transcutaneous Electrical Nerve Stimulation
Intervention Type
Device
Intervention Name(s)
TENS
Intervention Description
Transcutaneous electrical nerve stimulation
Intervention Type
Device
Intervention Name(s)
Sham TENS
Intervention Description
Sham Transcutaneous electrical nerve stimulation
Primary Outcome Measure Information:
Title
WOMAC pain subscale
Time Frame
End of treatment (at 3 weeks)
Secondary Outcome Measure Information:
Title
WOMAC global subscale
Time Frame
Baseline, end of treatment (at 3 weeks), 3-month follow-up
Title
WOMAC physical function subscale
Time Frame
Baseline, end of treatment (at 3 weeks), 3-month follow-up
Title
Overall pain measured on VAS
Time Frame
Baseline, end of treatment (at 3 weeks), 3-month follow-up
Title
Hospital anxiety and depression scale
Time Frame
Baseline, end of treatment (at 3 weeks), 3-month follow-up
Title
Aberdeen measure of participation
Time Frame
Baseline, end of treatment (at 3 weeks), 3-month follow-up
Title
Mean analgesic intake per patient
Time Frame
Baseline, end of treatment (at 3 weeks), 3-month follow-up
Title
Number of drop-outs because of adverse events
Time Frame
End of treatment (at 3 weeks), 3-month follow-up
Title
Number of patients experiencing local adverse events
Time Frame
End of treatment (at 3 weeks), 3-month follow-up
Title
Number of patients experiencing any side effects
Time Frame
End of treatment (at 3 weeks), 3-month follow-up
Title
Number of patients experiencing serious side effects
Time Frame
End of treatment (at 3 weeks), 3-month follow-up
Title
Number of drop-outs
Time Frame
End of treatment (at 3 weeks), 3-month follow-up
Title
WOMAC pain subscale
Time Frame
Baseline, third treatment session, 3-month follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and women of at least 18 years of age Clinical or radiological diagnosis of knee OA according to the criteria of the American College of Rheumatology Knee pain lasting for six months or longer Radiographic evidence of at least one osteophyte at the tibiofemoral joint (Kellgren-Lawrence grade ≥ 2) or one or more of the following signs and symptoms in the knee; restricted range of motion, pain in motion, crepitations, morning stiffness Written informed consent Exclusion Criteria Patients diagnosed with rheumatoid arthritis or other musculoskeletal diseases affecting lower extremities Relevant effusion in the index knee Known current or remittent cancer Carry cardiac pacemaker or defibrillator in situ Knee surgery in previous 6 months Received treatment with arthrocentesis Intra-articular injection of steroids in previous 3 months Inability to understand instructions or to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephan Reichenbach, MD
Organizational Affiliation
Institute of Social and Preventive Medicine (ISPM), University of Bern
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Peter Jüni, Prof.
Organizational Affiliation
Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael's Hospital, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Canada
Official's Role
Study Director
Facility Information:
Facility Name
Institute of Social and Preventive Medicine (ISPM), University of Bern
City
Bern
ZIP/Postal Code
3012
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
34826572
Citation
Reichenbach S, Juni P, Hincapie CA, Schneider C, Meli DN, Schurch R, Streit S, Lucas C, Mebes C, Rutjes AWS, da Costa BR. Effect of transcutaneous electrical nerve stimulation (TENS) on knee pain and physical function in patients with symptomatic knee osteoarthritis: the ETRELKA randomized clinical trial. Osteoarthritis Cartilage. 2022 Mar;30(3):426-435. doi: 10.1016/j.joca.2021.10.015. Epub 2021 Nov 23.
Results Reference
derived

Learn more about this trial

Effect of Transcutaneous Electrostimulation (TENS) on Pain and Physical Function in Patients With Knee Osteoarthritis

We'll reach out to this number within 24 hrs